塞德斯医疗(CLDX)
搜索文档
Celldex Therapeutics(CLDX) - 2021 Q4 - Earnings Call Transcript
2022-03-01 09:57
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Q4 2021 Earnings Conference Call February 28, 2022 4:30 PM ET Company Participants Sarah Cavanaugh - Senior Vice President, Corporate Affairs and Administration Anthony Marucci - Co-founder, President and Chief Executive Officer Tibor Keler - Co-Founder and Chief Scientific Officer Diane Young - Senior Vice President and Chief Medical Officer Margo Heath-Chiozzi - Senior Vice President of Regulatory Affairs Diego Alvarado - Executive Director of Research Conference C ...
Celldex Therapeutics(CLDX) - 2020 Q3 - Quarterly Report
2020-11-06 05:06
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $.001 CLDX Nasdaq Capital Market FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC ...
Celldex Therapeutics(CLDX) - 2020 Q2 - Earnings Call Transcript
2020-08-07 09:49
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Q2 2020 Earnings Conference Call August 6, 2020 4:30 PM ET Company Participants Sarah Cavanaugh – Senior Vice President, Corporate Affairs and Administration Anthony Marucci – Co-founder, President and Chief Executive Officer Diane Young – Senior Vice President and Chief Medical Officer Sam Martin – Senior Vice President and Chief Financial Officer Margo Heath-Chiozzi – Senior Vice President, Regulatory Affairs Conference Call Participants Kristen Kluska – Cantor Fit ...
Celldex Therapeutics(CLDX) - 2020 Q2 - Quarterly Report
2020-08-07 04:21
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 000-15006 CELLDEX THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware No. 13-3191702 (State or other jurisdiction of incorporation or organization ...